| Literature DB >> 25058758 |
Kei Ogino1, Masanobu Nakajima, Miyako Kakuta, Mitsuhiro Hayashi, Satoru Yamaguchi, Takashi Tsuchioka, Keiichi Kubota, Setsu Sakamoto, Hiroyuki Kato.
Abstract
Neoadjuvant chemotherapy (NAC) is effective in down-staging a primary tumor before surgery, and quick differentiation between responders to NAC and nonresponders is needed. We investigated the utility of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) in evaluating the therapeutic effectiveness of NAC. We investigated 25 patients who underwent NAC for stage II and III noninflammatory breast cancer. FDG-PET/CT was undertaken before and after NAC to determine the maximum standardized uptake value (SUVmax) reduction rate. Findings were compared with postoperative histopathologic evaluation of therapeutic response. It was not possible to accurately assess tumor response to NAC using CT. However, using the SUVmax reduction rate, we noted a significant difference (P=0.0420) between patients who were responsive and nonresponsive to NAC. The sensitivity and specificity were as high as 83.3% and 78.9%, respectively. This study demonstrated that FDG-PET/CT can differentiate responders from nonresponders. This improves patient management by avoiding unnecessary chemotherapy.Entities:
Keywords: Breast cancer; Computed tomography; Diagnostic imaging; Neoadjuvant chemotherapy; Positron emission tomography
Mesh：
Substances：
Year: 2014 PMID： 25058758 PMCID： PMC4114354 DOI： 10.9738/INTSURG-D-13-00044.1
Source DB: PubMed Journal: Int Surg ISSN： 0020-8868